Post radiation hysterectomy in locally advanced cervical cancer: Outcomes and dosimetric impact

• Published in: Radiotherapy and oncology 2016-09, Vol.120 (3), p.460-466
• Main Authors: Mazeron, Renaud, Gouy, Sébastien, Chargari, Cyrus, Rivin del Campo, Eleonor, Dumas, Isabelle, Mervoyer, Augustin, Genestie, Catherine, Bentivegna, Enrica, Balleyguier, Corinne, Pautier, Patricia, Morice, Philippe, Haie-Meder, Christine
• Format: Article
• Language: English
• Subjects: Adult; Aged; Brachytherapy - adverse effects; Brachytherapy - methods; Cervix cancer; Chemoradiation; Chemoradiotherapy; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Female; Hematology, Oncology and Palliative Medicine; Humans; Hysterectomy; Hysterectomy - adverse effects; Hysterectomy - methods; Image-guided adaptive brachytherapy; Late morbidity; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Staging; Neoplasm, Residual; Radiometry - methods; Radiotherapy, Conformal - methods; Radiotherapy, Image-Guided - adverse effects; Radiotherapy, Image-Guided - methods; Rectum - radiation effects; Treatment Outcome; Urinary Bladder - radiation effects; Uterine Cervical Neoplasms - diagnostic imaging; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - therapy
• ISSN: 0167-8140; 1879-0887
• DOI: 10.1016/j.radonc.2016.07.010

Abstract Purposes Firstly, to evaluate the impact of completion hysterectomy after chemoradiation and image-guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer. Secondly, to assess a potential differential dose–effect relationship for the rectum and bladder according to the realization of hysterectomy. Material and methods Two cohorts of patients were identified, differing by the realization of completion hysterectomy. Inclusions were limited to FIGO stage I–II, with no para-aortic involvement. All patients received a combination of pelvic chemoradiation followed by IGABT. Their outcomes and morbidity were reviewed. Log-rank tests were used to compare survivals. Probit analyses were performed to study dose–volume effect relationships. Results The two cohorts comprised 54 patients in the completion surgery group and 157 patients in the definitive radiotherapy group. They were well balanced, except for the mean follow-up, significantly longer in the post hysterectomy cohort and the use of PET-CT in the work-up, more frequent in the definitive radiotherapy cohort. Although less local relapses were reported in the hysterectomy group, the 5-year disease-free and overall survival did not differ between groups. The cumulative incidence of severe late morbidity was significantly increased in the hysterectomy cohort: 22.5% versus 6.5% at 5 years ( p = 0.016). Dose–volume effects were observed for the bladder, with the D2cm3 corresponding with a 10% probability of late severe morbidity urinary events (ED10 ) of 67.8 Gy and 91.9 Gy in the hysterectomy and definitive radiotherapy cohorts, respectively. A D90 CTVHR of 85 Gy (planning aim) corresponded with a 93.3% rate of local control in the definitive radiotherapy cohort whereas it corresponded with a 77.3% chance to have a good histologic response (complete response or microscopic residual disease) in the hysterectomy group. Conclusion No benefit from completion hysterectomy in terms of overall or disease-free survival rates was observed, which was moreover responsible for an increase of the severe late morbidity. The realization of post-radiation hysterectomy resulted in a shift of the ED10 of 24.1 Gy.